HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

Purinostat Mesylate (PM) is a novel highly selective and active HDAC I/IIb inhibitor, and the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin completely can overcome PM's poor solubility and improves its stability and pharmacokinetic properties. Her...

詳細記述

書誌詳細

出版年:	Bioactive Materials
主要な著者:	Qiang Qiu, Linyu yang, Yunyu Feng, Zejiang Zhu, Ning Li, Li Zheng, Yuanyuan Sun, Cong Pan, Huandi Qiu, Xue Cui, Wei He, Fang Wang, Yuyao Yi, Minghai Tang, Zhuang Yang, Yunfan Yang, Zhihui Li, Lijuan Chen, Yiguo Hu
フォーマット:	論文
言語:	英語
出版事項:	KeAi Communications Co., Ltd. 2023-03-01
主題:	Chronic myelogenous leukemia Leukemia stem cell Selective HDAC I/IIb inhibitor GLS1 Mouse model
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2452199X2200336X